MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414726 | Name: Tunlametinibum
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tunlametinibum is a tyrosine kinase inhibitor and antineoplastic

Chemical Structure

Tunlametinibum
Tunlametinibum
CAS#1801756-06-8

Theoretical Analysis

MedKoo Cat#: 414726

Name: Tunlametinibum

CAS#: 1801756-06-8

Chemical Formula: C16H12F2IN3O3S

Exact Mass: 490.9612

Molecular Weight: 491.25

Elemental Analysis: C, 39.12; H, 2.46; F, 7.73; I, 25.83; N, 8.55; O, 9.77; S, 6.53

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
25mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tunlametinibum; Tunlametinib
IUPAC/Chemical Name
4-fluoro-5-(2-fluoro-4-iodoanilino)-N-(2- hydroxyethoxy)-1,3-benzothiazole-6-carboxamide
InChi Key
UFZJUVFSSINETF-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H12F2IN3O3S/c17-10-5-8(19)1-2-11(10)21-14-9(16(24)22-25-4-3-23)6-12-15(13(14)18)20-7-26-12/h1-2,5-7,21,23H,3-4H2,(H,22,24)
SMILES Code
O=C(C1=C(NC2=CC=C(I)C=C2F)C(F)=C3N=CSC3=C1)NOCCO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 491.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Keam SJ. Tunlametinib: First Approval. Drugs. 2024 Aug;84(8):1005-1010. doi: 10.1007/s40265-024-02072-x. Epub 2024 Jul 22. PMID: 39034326. 2: Shi Y, Han X, Zhao Q, Zheng Y, Chen J, Yu X, Fang J, Liu Y, Huang D, Liu T, Shen H, Luo S, Yu H, Cao Y, Zhang X, Hu P. Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open- label, single-arm, multicenter, phase I study. Exp Hematol Oncol. 2024 Jun 12;13(1):60. doi: 10.1186/s40164-024-00528-0. PMID: 38867257; PMCID: PMC11167782. 3: Liu Y, Cheng Y, Huang G, Xia X, Wang X, Tian H. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Front Pharmacol. 2023 Sep 21;14:1271268. doi: 10.3389/fphar.2023.1271268. PMID: 37808191; PMCID: PMC10557067. 4: Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, Chen J, Huang G, Zhang P, Cheng Y, Liu J, Liu J, Zhang J, Wu D, Chen Y, Ma X, Pan H, Jiang R, Liu X, Ren X, Tian H, Jia Z, Guo J, Si L. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2024 May;202:114008. doi: 10.1016/j.ejca.2024.114008. Epub 2024 Mar 11. PMID: 38479118. 5: Zhao Q, Wang T, Wang H, Cui C, Zhong W, Fu D, Xi W, Si L, Guo J, Cheng Y, Tian H, Hu P. Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma. Front Pharmacol. 2022 Nov 1;13:1039416. doi: 10.3389/fphar.2022.1039416. PMID: 36386136; PMCID: PMC9663925. 6: Wang Y, Xu G, Xia H. Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic. Br J Dermatol. 2025 May 9:ljaf178. doi: 10.1093/bjd/ljaf178. Epub ahead of print. PMID: 40341941.